| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.65 |
| 52 Week High | CN¥27.50 |
| 52 Week Low | CN¥14.05 |
| Beta | 1.11 |
| 11 Month Change | -10.34% |
| 3 Month Change | -17.70% |
| 1 Year Change | -41.16% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.89% |
Recent News & Updates
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Shareholder Returns
| 301211 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.2% | -2.6% | -2.7% |
| 1Y | -41.2% | -15.9% | -17.4% |
Return vs Industry: 301211 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 301211 underperformed the CN Market which returned -17.4% over the past year.
Price Volatility
| 301211 volatility | |
|---|---|
| 301211 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 301211's share price has been volatile over the past 3 months.
Volatility Over Time: 301211's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,012 | Qun Liang | www.biocause.com |
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Fundamentals Summary
| 301211 fundamental statistics | |
|---|---|
| Market cap | CN¥4.22b |
| Earnings (TTM) | CN¥173.57m |
| Revenue (TTM) | CN¥607.80m |
24.3x
P/E Ratio6.9x
P/S RatioIs 301211 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301211 income statement (TTM) | |
|---|---|
| Revenue | CN¥607.80m |
| Cost of Revenue | CN¥352.26m |
| Gross Profit | CN¥255.54m |
| Other Expenses | CN¥81.97m |
| Earnings | CN¥173.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.60 |
| Gross Margin | 42.04% |
| Net Profit Margin | 28.56% |
| Debt/Equity Ratio | 0% |
How did 301211 perform over the long term?
See historical performance and comparison